Pharmaceutical Technology

SEPTEMBER 22, 2022

The pharmaceutical company is well on its way to achieving its goals with successful full reimbursements, already confirmed in the United Kingdom ( UK), and Sweden. GlobalData is the parent company of Pharmaceutical Technology.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA Dosage 52

The Thyroid Pharmacist

NOVEMBER 29, 2023

The truth is that most supplement companies do not undergo the same scrutiny and testing that pharmaceutical products do, because many of the tests which are required of pharmaceutical companies are voluntary for supplement companies. We have 270 expiring in March 2025.) We have 299 expiring in March 2025.)

Health and Personal Care Stores 53

Health and Personal Care Stores Immunization Labelling Dosage 53

Pharmaceutical Technology

OCTOBER 31, 2022

Two categories of novel therapies stand out: cell therapies and therapies with novel MOAs, with new products in each category being forecast to launch between 2023 and 2025. The OA space has long been dominated by large pharmaceutical companies such as Bayer, Pfizer, and Eli Lilly. of the 7MM sales, respectively.

Compounding 59

Compounding Pharmaceutical Companies Pharmaceutical Companies 59

European Pharmaceutical Review

MARCH 7, 2024

Lastly, there is growing prominence and interest in radioligand therapeutics within major pharmaceutical companies, who are increasingly investing in this field, evident through recent acquisitions of Point Biopharma and RayzeBio. What makes targeted alpha therapies a promising new approach against cancer?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunization FDA 52

pharmaphorum

MAY 10, 2022

Jamie Phares, managing director, The Janssen Pharmaceutical Companies of Johnson & Johnson in the Gulf Cooperation Council (GCC), talks about how the healthcare industry needs to come together to reduce its environmental impact and further protect public health. About the author.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Hospitals 52

pharmaphorum

JANUARY 10, 2023

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. It flows from every direction in torrents to create huge opportunities to address the world’s mounting health issues.

Compounding 98

Compounding Insurance Pharmaceutical Companies Pharmaceutical Companies 98

pharmaphorum

OCTOBER 13, 2022

However, patent protection remains in some major markets, including France, Italy, Spain, and the UK until 2025. The question is whether other major pharmaceutical companies will be attracted to the space – particularly when areas such as oncology and orphan drugs currently provide a larger return on investment.

Communication 96

Communication Pharmaceutical Companies Pharmaceutical Companies 96

The Checkup by Singlecare

OCTOBER 27, 2023

The earliest date that a generic version could be available is in 2025. One place to start is to research any patient assistance program offered by the manufacturing pharmaceutical company, Bausch & Lomb. Related: Vyzulta side effects What is the generic for Vyzulta? Is Vyzulta covered by insurance?

Insurance 52

Insurance Pharmaceutical Companies Pharmaceutical Companies FDA 52

Pharmaceutical Technology

JUNE 19, 2023

Pharmaceutical companies are putting their trust in the immense potential this new generation of medicine has for treating individuals with rare genetic diseases, which currently affect an estimated 280 million patients worldwide.

Packaging 52

Packaging Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Viseven

JANUARY 4, 2023

As any new particular drug should be approved before becoming a consumable product, pharmaceutical companies must conduct research and drug trials during drug discovery. The post The Use of Artificial Intelligence in the Pharmaceutical Industry appeared first on Viseven.

Medical Records 52

Medical Records Pharmaceutical Companies Pharmaceutical Companies Communication 52

pharmaphorum

JULY 1, 2021

My SynBioBeta panel discussion was about the shape of biopharma in 2025 – a seemingly futuristic time that’s now less than four years away. Tanja Dowe is the CEO of Debiopharm Innovation Fund, the strategic investment arm of the Swiss pharmaceutical company Debiopharm. About the interviewee.

Pharmaceutical Companies 77

Pharmaceutical Companies Pharmaceutical Companies Patient Care Vaccines 77

pharmaphorum

APRIL 19, 2022

“In a situation where most of the development of treatments in Korea is mostly centred on cancer and metabolic diseases, I noticed that there weren’t any companies that were focusing on sensory diseases.”. Kim says the Dry Eye Disease market is large and growing, with analysts predicting it will hit $6 billion USD by 2025.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication FDA 52

pharmaphorum

MARCH 12, 2021

Behind all of these are massive and growing volumes of data that life sciences companies generate, manage and analyse to secure breakthroughs. One estimate [1] suggests that by 2025 more than 60 million patients will have their genome sequenced. And those volumes will only increase.

Vaccines 110

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 110

pharmaphorum

DECEMBER 21, 2021

By 2025, it is expected that 70 million genomes will be sequenced; a factor that Dr Hackett stated could mean that Rare Diseases “are potentially not as rare as we think…and with this extra information, we’re going to be able to accelerate this field faster.”.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Hospitals FDA 98

pharmaphorum

OCTOBER 12, 2022

As technology has evolved, biotech and pharmaceutical companies have increasingly leaned on AI to support drug development – including to make sense of the vast amounts of healthcare data available to them. By 2025, pharma’s investment in AI is expected to reach $3 billion. Forging an AI-enabled path toward precision medicine.

Immunization 102

Immunization Vaccines Pharmaceutical Companies Pharmaceutical Companies 102

Pharmaceutical Technology

MAY 23, 2023

The recent legislative reform proposals put forward by the European Commission (EC) have sparked significant discontent among pharmaceutical companies. This blog explores the key areas of concern for pharmaceutical companies and some of the potential implications of these reforms.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Packaging 52

PharmaShots

MAY 23, 2023

Propelled by constant innovatory winds, the Cell and Gene therapy market is anticipated to grow by 20 percent year-over-year through 2025. BMS's subsidiary, Celgene Corporation, is a pharmaceutical company primarily focusing on developing cancer treatment immunotherapies. With a total revenue of $52B, Merck & Co.

FDA 58

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 58

pharmaphorum

OCTOBER 18, 2021

8 It’s encouraging to see this as one of the goals in the EMA’s 2025 Regulatory Sciences Strategy. What remains very clear is that collaboration between sponsor companies, health authorities and other stakeholders will be required to move this forward. Real-time sharing of data.

Vaccines 137

Vaccines Pharmaceutical Companies Pharmaceutical Companies Documentation 137

pharmaphorum

JANUARY 14, 2021

Not so China, and especially not so the lead five European countries – on average European pharmaceutical companies saw a loss of 30% of the interactive time they previously had with healthcare professionals in 2020. Up to November, the US and Japan actually saw increases in interactive time in 2020. Pharma pivots East.

Pharmaceutical Companies 65

Pharmaceutical Companies Pharmaceutical Companies Labelling 65

The Checkup by Singlecare

JANUARY 18, 2024

The patent protection for Nexplanon typically prevents other pharmaceutical companies from creating a generic version until the patent expires. in 2027 and other countries in 2025, when a generic version may be approved. Currently, there isn’t a generic equivalent available on the market.

Insurance 52

Insurance Insurance Coverage Packaging Pharmaceutical Companies 52

pharmaphorum

DECEMBER 6, 2022

The research programme was officially launched at the end of October 2022, and has the aim of building a resource of five million individuals’ information by 2025. It is estimated that this will reach 70% by 2035. Industry interest.

Medical Records 97

Medical Records Compounding Pharmaceutical Companies Pharmaceutical Companies 97

PharmaShots

JUNE 7, 2023

To further expedite the introduction of the biosimilar globally, EirGenix has been in talks with global pharmaceutical companies about licensing the marketing rights to EG1206A 5. The P-III trial of EG1206A is expected to be initiated shortly, estimated that the evaluation of the primary EPs will be completed within 2yrs.

FDA 40

FDA Packaging Pharmaceutical Companies Pharmaceutical Companies 40

pharmaphorum

JANUARY 6, 2022

The period 2021-2025 was always going to be one of relatively low loss of exclusivity cost relief, with 18% of, combined with unprecedented levels of COVID-19 related spend, medicines budgets will be challenged for years to come. In our nine for 2021 predictions, we called out post-pandemic launch as a key area of concern.

Vaccines 108

Vaccines Pharmaceutical Companies Pharmaceutical Companies 108

ISPE

MARCH 6, 2023

link] A recent study published by My Green Lab 2 presented data from 74 biotechnology and pharmaceutical companies tracking the change in scope 1, 2, and 3 carbon intensity (measured in tons of CO2 emitted vs. the company’s revenue in USD) since 2015. For pharmaceutical companies, purchased goods (e.g.,

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies Compounding 52

pharmaphorum

AUGUST 8, 2021

Vectura had withdrawn its backing for PMI after the latest Carlyle offer came through, but at the time of writing hadn’t yet responded to the latest bid from the tobacco company.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

MARCH 22, 2023

Large-molecule drugs such as biologics are particularly sensitive to foreign contamination and E&L interaction, making these issues key concerns for pharmaceutical companies. From 2025, it will be substituted with a new chapter on functional tests for the complete system.”

Packaging 52

Packaging Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

APRIL 25, 2023

A few months later, the board of the nonprofit Vaccine Alliance Gavi approved an initial investment of nearly $160 million, to be given between 2022 and 2025, to support the rollout of the malaria vaccine in GAVI-eligible countries. However, making sure the vaccine reaches everyone can be challenging due to the storage requirements.

Vaccines 69

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 69

Pharmaceutical Technology

DECEMBER 22, 2022

The new joint procedure will launch in Q1 2025 for oncology medicines and other advanced therapy medicinal products and extend to orphan drugs in 2028. By 2030, JCAs will be carried out on all medicinal products with an EMA-issued MA. Will the joint procedure drive positive change?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Labelling Communication 52

Pharmaceutical Technology

APRIL 24, 2023

Meanwhile, the Indian biologics market is expected to grow to $12 billion by 2025, with a compound annual growth rate (CAGR) of 22%. As a result, some pharmaceutical companies are turning to third parties. Moreover, skilled manpower is required to run these facilities.

Vaccines 52

Vaccines Compounding Pharmaceutical Companies Pharmaceutical Companies 52